Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018. While some therapies in development hold promise, most have less favorable efficacy, safety and tolerability and/or delivery features compared with bevacizumab/paclitaxel/carboplatin.
"The bevacizumab/paclitaxel/carboplatin regimen attains current and future gold-standard status based on its superior overall survival in patients with advanced non-small-cell lung cancer," stated Decision Resources Analyst Laila Siddique.
The new report entitled Advanced Non-Small-Cell Lung Cancer: Lack of Efficacious Therapies in Development Presents Opportunity for an Agent That Can Increase Overall Survival also finds that a drug's effect on overall survival is the attribute that most influences surveyed oncologists prescribing decisions in advanced non-small-cell lung cancer. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage over sales leader bevacizumab/paclitaxel/carboplatin on this attribute.
"Oncologists we surveyed are enthusiastic about the improvements seen in efficacy resulting from the addition of bevacizumab to chemotherapeutic agents," added Ms. Siddique. "This enthusiasm however, stems solely from the ability of the regimen to increase overall survival beyond that seen with chemotherapy doublets."
New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts